Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours

Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at NCI, shared on X:

“Cabozantinib/Nivolumab and Cabozantinib/Nivolumab/Ipilimumab have shown promising efficacy and safety in patients with metastatic urothelial carcinoma, metastatic renal cell carcinoma and rare GU tumors in a dose-escalation phase I study.”

Additional information.
Source: Andrea Apolo/X